Category: St. Jude Medical
Renal denervation has won a lot of praise as a potential solution for patients with resistant hypertension, but the excessive celebration of early clinical trial results may be setting everyone up for a major letdown and a harsh backlash. This week cardiologists at the Transcatheter Cardiovascular Therapeutics conference, including those involved with Medtronic's and Boston Scientific's clinical trials, warned of the dangers of exaggeration.
Renal denervation is still in its youth, but the limited clinical trials and lack of substantial confirmation hasn't curbed much of the hype for the technology as a means of treating patients with resistant hypertension.
Medical device titan St. Jude Medical continues gathering data on its Portico transcatheter aortic valve implantation system, releasing positive 30-day clinical trial results for 2 sizes of the device.
German medical device maker Transcatheter Technologies GmbH announces 1st-in-man implantation of its repositionable Trinity transcatheter aortic valve system, treading into territory already marked by medtech giants Medtronic and St. Jude Medical.
MASSDEVICE ON CALL — Germany-based medical device company Transcatheter Technologies GmbH is making a bold stride into the transcatheter aortic valve implantation space, announcing 1st-in-man implantation of a device it says it intends to be the "the world's best repositionable heart valve."
Panelists at this year's Transcatheter Cardiovascular Therapeutics symposium debate whether left atrial appendage occlusion device makers can compete against anti-coagulant drug makers, which have long held a coveted spot as the gold standard in stroke prevention for patients with atrial fibrillation.
Makers of atrial appendage occlusion devices sound off on whether the implants should continue to rely on hooks for anchoring, like St. Jude Medical's Amplatzer Amulet does, or find novel ways to keep the devices in place, the way some new device makers propose.
St. Jude Medical's Amulet LAA occluder
The U.S. Patent & Trademark Office declines to review a patent in St. Jude Medical's long-running war with rival Volcano Corp.
St. Jude Medical says the FDA approved its Ilumien Optis device, designed to measure blood flow and provide images of the heart during stenting procedures.
St. Jude Medical (NYSE:STJ) said today that the FDA granted pre-market approval for its next-generation Ilumien Optis device, which combines a pair of technologies to help guide physicians during stenting procedures.